Eli Lilly and Company has reported worldwide revenue of $28.32bn for full-year 2021, indicating a 15% rise against $24.54bn for full-year 2020.

A 10% revenue growth, excluding the Covid-19 antibodies, was recorded during this period.

For the 12 months ending on 31 December 2021, Covid-19 antibodies generated worldwide revenue of $2.24bn compared with $871.2m in 2020. 

In the US, revenue for the full year stood at $16.81bn, representing an 18% rise. This increase was driven by a 19% growth in volume and partially offset by a 1% decline due to reduced realised prices. 

Crucial growth products, including Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Retevmo and Emgality contributed to the rise in US volume.

During the year, operating income surged 5% to nearly $6.36bn from $6.06bn in 2020. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Net income and earnings per share (EPS) for the full year declined 10% to $5.58bn and $6.12, as against $6.19bn and $6.79, respectively, in 2020.

Furthermore, the company’s worldwide revenue in the fourth quarter (Q4) of 2021 grew 8% to $8bn from $7.4bn during the same quarter last year.

For the quarter, EPS declined by 18% to $1.90 on a reported basis from $2.32 in Q4 2020.

Eli Lilly chair and CEO David Ricks said: “Lilly had a remarkable year of growth and pipeline success in 2021, despite the continued hardships from the pandemic. 

“We have tremendous momentum moving into 2022 and beyond with strong revenue expectations, limited patent exposure and an exciting pipeline of potential new medicines, which we hope will give us the opportunity to positively impact millions more lives in meaningful ways.”

Last month, the US Food and Drug Administration (FDA) revised authorisations for two monoclonal antibody treatments Lilly and Regeneron to limit their use.